Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2025 | Outperform → Mkt Perform | Raymond James | |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 12/19/2024 | $275.00 | Buy | Guggenheim |
| 12/13/2024 | $290.00 | Neutral → Buy | BofA Securities |
| 10/31/2024 | $285.00 | Peer Perform → Outperform | Wolfe Research |
| 10/1/2024 | $315.00 | Overweight | Stephens |
| 8/28/2024 | $280.00 | Equal Weight | Wells Fargo |
| 6/3/2024 | $295.00 | Buy | Jefferies |
Raymond James downgraded Danaher from Outperform to Mkt Perform
Scotiabank initiated coverage of Danaher with a rating of Sector Perform
Guggenheim initiated coverage of Danaher with a rating of Buy and set a new price target of $275.00
144 - DANAHER CORP /DE/ (0000313616) (Subject)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C
WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service. Ms. Sawyer Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair. Rainer Blair com
Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink's CleanCap mRNA capping technology for non-commercial use TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those deve
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14.Revenues increased 2.0% year-over-year to $6.5 billion and non-GAAP core revenue increased 1.0%.Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.5 billion.Key Full Year 2024 Results Net earnings were $3.9 billion, or $5.29 per diluted common share and non-GAAP ad
Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14.Revenues increased 2.0% year-over-year to $6.5 billion and non-GAAP core revenue increased 1.0%.Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.5 billion.Key Full Year 2024 Results Net earnings were $3.9 billion, or $5.29 per diluted common share and non-GAAP ad
WASHINGTON, Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the Company's previously announced guidance of a low-single digit percent decline.As previously announced, Danaher will hol
WASHINGTON, Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)